Axsome Therapeutics, Inc.
AXSMNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M | — | — |
| Operating income | −$166.8M | −$280.6M | −$231.8M | −$179.8M | −$124.7M | −$99.1M |
| Net income | −$183.2M | −$287.2M | −$239.2M | −$187.1M | −$130.4M | −$32.5M |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M | $186.1M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M | $72.3M |
| Equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M | $113.8M |
| EPS (diluted) | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 |
| Shares out. | 48.8M | 47.4M | 43.5M | 38.5M | 37.4M | 37.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −26.1%
- Net margin
- −28.7%
- Return on equity
- −207.5%
- Return on assets
- −26.6%
- Return on capital (ROCE)
- −53.6%
- Liabilities / assets
- 87.2%
- Debt / equity
- 6.81×
- Book value / share
- $1.81
- Revenue growth (YoY)
- 65.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.64distress
- Accruals / assets
- −13.0%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- SYMBRAVOJan 30, 2025
- AUVELITYAug 18, 2022
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2025-12Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
- Phase 4Recruitingreadout ~2026-03A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Phase 3Recruitingreadout ~2026-12Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
- Phase 3Enrolling By Invitationreadout ~2026-12Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
- Phase 3Recruitingreadout ~2028-03Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
- Phase 3Recruitingreadout ~2028-12Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 26, 2026
- Rtw Investments, LpPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jacobson Mark L.Officer — Chief Operating Officer | May 4, 2026 | Option exercise | 4,517 | $12.95 |
| Maizel AriOfficer — Chief Commercial Officer | Apr 22, 2026 | Option exercise | 7,500 | $70.73 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.8M | 2.9 | +1.0% |
| Apr 30, 2026 | 2.7M | 3.4 | +2.6% |
| Apr 15, 2026 | 2.7M | 4.5 | -5.4% |
| Mar 31, 2026 | 2.8M | 4.9 | +2.4% |
| Mar 13, 2026 | 2.8M | 5.0 | +6.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Other material eventMay 4, 2026
- Other material eventApr 30, 2026
- Other material eventApr 1, 2026
- Results of operationsFeb 23, 2026
- Other material eventFeb 17, 2026
- Results of operations · Other material eventJan 12, 2026
- Other material eventDec 31, 2025
- Results of operations · Other material eventNov 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.